To assess the efficacy of CCR2 antagonist and anti-PD-1 combination treatment in models beyond bladder cancer as well as in metastatic disease, we examined the efficacy of this combination in the treatment of B16F10 melanoma pulmonary metastases. Here, PDCD1 is linked to urinary bladder carcinoma.